CRISPR Therapeutics Deserves Its Lofty Valuation Even With Conservative Forecasts
RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating
Cathie Wood Stocks (CRSP, SHOP, SQ) Could Actually Be Darn Good Picks
With 66% Ownership of the Shares, CRISPR Therapeutics AG (NASDAQ:CRSP) Is Heavily Dominated by Institutional Owners
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Express News | Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older
